Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

BACKGROUND: Immunotherapies have demonstrated efficacy across a diverse set of tumors supporting further evaluation in glioblastoma. The objective of this study was to evaluate the safety/tolerability and describe immune-mediated effects of nivolumab ± ipilimumab in patients with recurrent glioblast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert, Zwirtes, Ricardo, Strauss, Lewis, Paliwal, Prashni, Harbison, Christopher T, Reardon, David A, Sampson, John H
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892140/
https://ncbi.nlm.nih.gov/pubmed/29106665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox208
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados